{
  "id": 6776,
  "url": "https://nnemf.org/research/6776-reduced-biophotonic-activities-and-spectral-blueshift-in-alzheimer",
  "title": "Reduced biophotonic activities and spectral blueshift in Alzheimer's disease and vascular dementia models with cognitive impairment.",
  "authors": [
    "Zhuo Wang",
    "Zhipeng Xu",
    "Yi Luo",
    "Sisi Peng",
    "Hao Song",
    "Tian Li",
    "Jiaxin Zheng",
    "Na Liu",
    "Shenjia Wu",
    "Junxia Zhang",
    "Lei Zhang",
    "Yuan Hu",
    "Yanping Liu",
    "Dongwei Lu",
    "Jiapei Dai",
    "Junjian Zhang"
  ],
  "journal": "Frontiers in aging neuroscience",
  "year": "2023",
  "doi": "10.3389/fnagi.2023.1208274",
  "pmid": "37727319",
  "abstract": "BACKGROUND: Although clinically, Alzheimer's disease (AD) and vascular dementia (VaD) are the two major types of dementia, it is unclear whether the biophotonic activities associated with cognitive impairments in these diseases share common pathological features. METHODS: We used the ultraweak biophoton imaging system (UBIS) and synaptosomes prepared by modified percoll method to directly evaluate the functional changes in synapses and neural circuits in AD and VaD model animals. RESULTS: We found that biophotonic activities induced by glutamate were significantly reduced and spectral blueshifted in synaptosomes and brain slices. These changes could be partially reversed by pre-perfusion of the ifenprodil, a specific antagonist of the GluN2B subunit of N-methyl-D-aspartate receptors (NMDARs). CONCLUSION: Our findings suggest that AD and VaD pathology present similar but complex changes in biophotonic activities and transmission at synapses and neural circuits, implying that communications and information processing of biophotonic signals in the brain are crucial for advanced cognitive functions.",
  "effect": "unclear",
  "evidence": "insufficient",
  "extraction": {
    "studyType": "animal",
    "studyTypeLabel": "Animal study",
    "effectDirection": "unclear",
    "evidenceLabel": "Insufficient",
    "population": "AD and VaD model animals",
    "sampleSize": "—",
    "exposure": "",
    "confidencePct": "74",
    "peerReviewed": "yes",
    "mainFindings": "Glutamate-induced biophotonic activities were significantly reduced and showed a spectral blueshift in synaptosomes and brain slices from AD and VaD model animals. These changes were partially reversed by pre-perfusion with ifenprodil, a GluN2B-containing NMDAR antagonist.",
    "outcomes": [
      "Glutamate-induced biophotonic activity in synaptosomes and brain slices",
      "Spectral shift (blueshift) of biophotonic emissions",
      "Reversibility of changes with ifenprodil (GluN2B antagonist)"
    ],
    "limitations": [
      "Sample size not reported in abstract",
      "Specific animal models and experimental conditions not detailed in abstract",
      "Not an EMF exposure study",
      "focuses on endogenous ultraweak biophoton signals"
    ],
    "keywords": [
      "Alzheimer's disease",
      "vascular dementia",
      "biophoton imaging",
      "ultraweak biophoton imaging system",
      "synaptosomes",
      "glutamate",
      "spectral blueshift",
      "NMDAR",
      "GluN2B",
      "ifenprodil",
      "synapses",
      "neural circuits",
      "cognitive impairment"
    ],
    "hubs": [],
    "raw": "{\n  \"study_type\": \"animal\",\n  \"exposure\": {\n    \"band\": null,\n    \"source\": null,\n    \"frequency_mhz\": null,\n    \"sar_wkg\": null,\n    \"duration\": null\n  },\n  \"population\": \"AD and VaD model animals\",\n  \"sample_size\": null,\n  \"outcomes\": [\n    \"Glutamate-induced biophotonic activity in synaptosomes and brain slices\",\n    \"Spectral shift (blueshift) of biophotonic emissions\",\n    \"Reversibility of changes with ifenprodil (GluN2B antagonist)\"\n  ],\n  \"main_findings\": \"Glutamate-induced biophotonic activities were significantly reduced and showed a spectral blueshift in synaptosomes and brain slices from AD and VaD model animals. These changes were partially reversed by pre-perfusion with ifenprodil, a GluN2B-containing NMDAR antagonist.\",\n  \"effect_direction\": \"unclear\",\n  \"limitations\": [\n    \"Sample size not reported in abstract\",\n    \"Specific animal models and experimental conditions not detailed in abstract\",\n    \"Not an EMF exposure study; focuses on endogenous ultraweak biophoton signals\"\n  ],\n  \"evidence_strength\": \"insufficient\",\n  \"confidence\": 0.74,\n  \"peer_reviewed_likely\": \"yes\",\n  \"keywords\": [\n    \"Alzheimer's disease\",\n    \"vascular dementia\",\n    \"biophoton imaging\",\n    \"ultraweak biophoton imaging system\",\n    \"synaptosomes\",\n    \"glutamate\",\n    \"spectral blueshift\",\n    \"NMDAR\",\n    \"GluN2B\",\n    \"ifenprodil\",\n    \"synapses\",\n    \"neural circuits\",\n    \"cognitive impairment\"\n  ],\n  \"suggested_hubs\": []\n}"
  },
  "synthesis": null,
  "synthesisStatus": "pending",
  "originalHref": "https://pubmed.ncbi.nlm.nih.gov/37727319/",
  "sourceUrl": "https://rfsafe.org/mel/paper.php?id=6776",
  "updated": "2026-03-07 23:01:55"
}